Pharmacy and Therapeutics Committee

The Idaho Medicaid Pharmacy and Therapeutics Committee (P&T Committee) is comprised of Idaho health practitioners – physicians, physician assistant, pharmacists – who are committed to providing the right care at the right price. This committee meets four times per year to review clinical evidence. The P&T Committee makes recommendations to the Department of Health and Welfare regarding drug safety and efficacy as well as prior authorization requirements. Cost modeling analysis is done by the department twice per year – following the committee meetings in May and November.

Preferred Drug List (PDL)

General P&T Information

2019 Meeting Dates:

April 19, 2019
May 17, 2019
October 18, 2019
November 15, 2019

Members

Voting Members

Andrei Rudyi, PharmD (Boise, serving since 2016)
Brian Crownover, M.D. (Meridian, serving since 2015)
Christopher Streeter, M.D. (Boise, serving since 2014)
David Calley, PharmD (Meridian, serving since 2018)
Jeffery Johnson, PharmD, PA (Eagle, serving since 2017)
Joseph Weatherly, D.O. (Idaho Falls, serving since 2017
Perry Brown, M.D. (Boise, serving since 2009)
Paul Driver, PharmD (Lewiston, serving since 2016)

Non-Voting Members

Mark Randleman, D.O. (Interim Medical Director)
Tamara Eide, PharmD (Medicaid Program Manager)
Alex Adams, PharmD, MPH (Executive director, Idaho Board of Pharmacy)

P&T Drug Review Schedule for 2019

P&T Meeting Dates	New Reviews	Re-Reviews
April 19, 2019 *		Angiotensin Modulators Angiotensin Modulator Combinations Antihypertensives, Sympatholytic Beta Blockers Calcium Channel Blockers PAH Agents, Oral and Inhaled Vasodilators, Coronary Anticoagulants Platelet Aggregation Inhibitors Lipotropics, Other Lipotropics, Statins Androgenic Agents BPH Treatments Bladder Relaxant Preparations Bone Resorption Suppression and Related Agents Phosphate Binders Growth Hormone Cystic Fibrosis, Oral Pancreatic Enzymes Proton Pump Inhibitors H. Pylori Treatments GI Motility, Chronic Ulcerative Colitis Agents Hepatitis C Agents (Interferons and Ribavirin only) Multiple Sclerosis Agents
May 17, 2019**	Antimigraine Agents, Calcitonin Gene-Related Proteins	Hypoglycemics, Metformins Hypoglycemics, Incretin Mimetics/Enhancers Hypoglycemics, Insulin Hypoglycemics, SGLT2 Hypoglycemics, TZD Hereditary Angioedema Agents Antivirals, Oral Antivirals, Topical Antibiotics, Inhaled Antibiotics, Topical Antibiotics, Vaginal Cephalosporins and Related Agents Fluroquinolones, Oral Macrolides Tetracyclines Antibiotics, GI Antifungals, Oral Antifungals, Topical Antiparasitics, Topical Immunosuppressants, Oral Antimigraine Agents, Triptans Analgesics, Narcotic long-acting Analgesics, Narcotic short-acting Opiate Dependence Skeletal Muscle Relaxants Antiemetics/Antivertigo Agents
October 18, 2019 ***		Anti-Allergens, Oral Antihistamines, Minimally Sedating Intranasal Rhinitis Epinephrine, Self-injected Immunomodulators, Atopic Dermatitis Immune Globulins Immunomodulators, Asthma Bronchodilators, Beta Agonist Glucocorticoids, Inhaled Leukotriene Modifiers COPD Agents Smoking Cessation Cytokine/CAM Agents Botulinum Toxins Ophthalmic Antibiotics Ophthalmic Antibiotic/Steroid Combinations Ophthalmic Antiinflammatories, Immunomodulators Ophthalmics for Allergic Conjunctivitis
November 15, 2019****		Otic Antibiotics NSAIDs Pain, Other Antipsychotics, Atypical Antipsychotics, Typical Antidepressants, Other Antidepressants, SSRIs Anticonvulsants Anxiolytics/Benzodiazepines Stimulants and Related Agents Sedative Hypnotics Alzheimer’s Agents Antiparkinsons Agents/Restless Leg Syndrome Movement Disorders Antihyperurecemics, Oral Colony Stimulating Factors Erythropoiesis Stimulating Proteins

*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 20, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the May meeting. These final decisions will be effective July 1, 2019.

**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 20, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective July 1, 2019.

***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the November meeting. These final decisions will be effective January 6, 2020.

****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective January 2, 2020.